Coronary Artery Bypass Graft Devices – Market Insights – United States

The mature US CABG device market will contract slightly through 2026 as procedure volumes decline due to increasing use of PCI for the treatment of CAD; however, rising interest in off-pump and minimally invasive approaches to CABG surgery will help to mitigate overall revenue declines to some extent.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for CABG devices in the US, with market projections across a 10-year period.

Surgical revascularization via CABG surgery for CAD patients is facing increasing competition from alternative treatments such as PCI and medical management. 

What is the growth trend for CABG procedure volumes in the US?

What impact will recent and ongoing clinical trials have on CABG procedure volumes and clinical guidelines for coronary revascularization in the US?

In which specific indications will CABG surgery experience increases in procedure volumes?

How will the complexity of cardiac surgery and the breakdown of concomitant procedures change in the US?

In the last two decades, continued technological improvement has led to the maturity of OPCAB surgery and the development of minimally invasive approaches to CABG surgery, such as MIDCAB, MICS CABG surgery, and TECAB

What is the current level of clinical support for OPCAB surgery? 

Is there an ongoing shift between ONCAB and OPCAB procedures?

What is the growth prospect for minimally invasive CABG procedures? 

Price competition will limit revenue growth potential, especially in light of increased cost-consciousness among health care facilities.  

Which segments will experience the most price competition?

In which segments and to what extent will adoption of premium-priced next-generation products offset the effects of price competition? 

What strategies can CABG device manufacturers adopt to address the increasing cost-consciousness among health care facilities? 

Table of contents